NextCell Pharma publishes its Interim Report 2 2024/2025

April 25, 2025

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period December 1, 2024 – February 28, 2025. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Second Quarter (2024-12-01 to 2025-02-28)

Operating income amounted to 3,417 (2,405) TSEK, of which Cellaviva contributed 3,248 (2,334) TSEK.
Net sales amounted to 3,248 (2,334) TSEK.
Profit/loss after financial items amounted to -8,198 (-10,093) TSEK.
Earnings per share* were -0.11 (-0.29) SEK.
Cash and cash equivalents amounted to 26,338 (30,393) TSEK.
Equity ratio** amounted to 83 (79) percent.

First Half Year (2024-09-01 to 2025-02-28)

Operating income amounted to 6,281 (7,099) TSEK, of which Cellaviva contributed 6,077 (6,580) TSEK.
Net sales amounted to 6,077 (6,580) TSEK.
Profit/loss after financial items amounted to -16,240 (-19,889) TSEK.
Earnings per share* were -0.40 (-0.58) SEK.

*Earnings per share: Net result for the period divided by the average number of shares. The average number of shares for the second quarter of 2024/2025: 73,091,327 (34,379,523) shares. The average number of shares for the first half year of 2024/2025: 73,091,327 (34,379,523) shares. The number of shares in NextCell as of 28 February 2024: 73,091,327 (34,379,523) shares.
**Equity ratio: Shareholders’ equity as a percentage of total assets.

Significant events and news during the second quarter

In December, NextCell reported new results from the ProTrans-Repeat study. "The results from theProTrans-Repeat study are very encouraging and show that repeated treatment can preserve and even improve insulin production over six years. This strengthens ProTrans' potential as a safe and effective treatment for modifying the progression of type 1 diabetes," comment- ed Mathias Svahn, CEO.
Mid Februari NextCell announced that all patients in the clinical trial ProTrans V, where ProTrans is used for the treatment of severe virus-induced pneumonia, had been treated.

Significant events after the reporting period

At the end of March NextCell Pharma announced that the company's Chief Scientific Officer (CSO), Dr Lindsay Davies had been elected to the board of ATMP Sweden.

In the beginning of April NextCell Pharma announced preliminary one-year results from the older age group (12–21 years) in the ongoing clinical trial ProTrans-Young. The study is evaluating the safety and efficacy of the company’s cell therapy, ProTrans, in preserving insulin production in young individuals newly diagnosed with type 1 diabetes, compared with placebo.
NextCell Pharma announced early April that Dr Lindsay Davies, Chief Scientific Officer at NextCell Pharma AB, had been elected Vice President Elect for Europe within the International Society for Cell and Gene Therapy (ISCT).
Mid April NextCell Pharma published an interview where the analyst Filip Einarsson from Redeye, who currently covering NextCell, discussed with Mathias Svahn questions regarding the latest results from ProTrans-YOUNG.

This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25-04-2025 07:30 CET.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma

For more information about Cellaviva, please contact
Sofie Falk Jansson, CEO Cellaviva AB
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
RedEye AB is assigned as Certified Adviser.
The company's shares are listed on the Nasdaq First North Growth Market.

About NextCell Pharma AB
NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes. NextCell owns Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use. NextCell also owns QVance which will offer quality control analytics for advanced therapy developers. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology.

Download attachment Read full press release on Cision (external link)

2026-03-13

ProTrans Phase II COVID-19 Trial Accepted for Publication in Cytotherapy

NextCell Pharma AB (“NextCell” or the “Company”) announces that the Phase II clinical trial evaluating ProTrans® (allogeneic Wharton’s Jelly-derived mesenchymal stromal cells) for respiratory complications associated with COVID-19 has been accepted for publication in Cytotherapy (https://www.isct-cytotherapy.org/article/S1465-3249(26)00736-X/abstract), the official journal of the International Society for Cell & Gene Therapy.

Read more Read more

2026-03-03

NextCell Pharma presents historical quarterly figures

At the Extraordinary General Meeting of NextCell Pharma AB (publ) (“NextCell” or the “Company”) held on 21 August 2025, it was resolved that the Company shall change its financial year from a broken financial year September–August to a calendar year January–December. The Company’s first full financial year in accordance with the calendar year will be 2026. To facilitate historical comparisons and enhance transparency for future reports that will follow the calendar year structure, the Company is today publishing financial information for the five most recent comparative quarters.

Read more Read more

2026-02-26

NextCell publishes Year-End Report 2024/2025

NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Year-End Report for the extended financial year September 1, 2024 – December 31, 2025. The report is available on the company´s website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period last year for the fourth quarter (October-December 2024) and twelve months (the previous fiscal year September 2023 - August 2024).

Read more Read more

2026-02-17

NextCell Participating in JETRO’s Japan Entry Acceleration Program

NextCell Pharma AB (“NextCell” or the “Company”) announces its participation in the Japan Entry Acceleration Program (“JEAP”) in regenerative medicine, an international accelerator initiative organized and funded by JETRO. NextCell is communicating its participation in connection with the Company’s current presence in Tokyo, where program activities and meetings with Japanese industrial, regulatory and financial stakeholders are now taking place.

Read more Read more

2026-02-03

Seven-year follow-up data from ProTrans-Repeat demonstrate sustained disease-modifying effects of ProTrans in type 1 diabetes

NextCell Pharma AB (“NextCell” or the “Company”) today announces long-term follow-up data from the ProTrans-Repeat study showing sustained preservation of endogenous insulin production in patients with newly diagnosed type 1 diabetes. The data extends to approximately 6 years after the last ProTrans infusion, corresponding to 7 to 7.5 years since the first infusion.

Read more Read more

2026-01-21

NextCell provides strategic update on focused market progression, highlighting Hong Kong as gateway to the Chinese market

NextCell Pharma AB (“NextCell” or the “Company”) provides a strategic update on its focused market progression strategy, aimed at accelerating value creation by advancing ProTrans™ in adult patients, where NextCell already has a strong clinical foundation, while simultaneously strengthening the company’s global partnering position. This approach builds on NextCell’s original development strategy and is designed to create multiple independent value drivers for the company.

Read more Read more

2026-01-21

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NEXTCELL PHARMA AB (PUBL)

The shareholders of NextCell Pharma AB (publ), reg. no. 556965-8361, (the "Company") are hereby invited to attend an extraordinary general meeting on Tuesday, 10th of February 2026, at 10:00 CET at Novum-huset, floor 6 (lift E), Hälsovägen 7, Huddinge. Registration for the meeting will commence at 09.30 CET.

Read more Read more

2026-01-21

NextCell decides to propose a directed share issue of SEK 15 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, HONG KONG, JAPAN, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. The Board of Directors of NextCell Pharma AB (“NextCell” or the “Company”) has resolved to propose to the extraordinary general meeting (the “Extraordinary General Meeting”) to resolve on a directed share issue comprising a total of 15,000,000 shares to a number of strategic investors at a subscription price of SEK 1.00 per share (the “Directed Issue”). Participating investors include both new investors and a number of larger existing shareholders. The Extraordinary General Meeting is planned to be held on Tuesday, 10 February 2026. Notice of the Extraordinary General Meeting will be announced separately.

Read more Read more